- Home
- RGEN vs CORT Comparison
RGEN vs CORT Comparison
Compare RGEN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGEN
- CORT
- Stock Information
- Founded
- RGEN 1981
- CORT 1998
- Country
- RGEN United States
- CORT United States
- Employees
- RGEN N/A
- CORT N/A
- Industry
- RGEN Medical/Dental Instruments
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- RGEN Health Care
- CORT Health Care
- Exchange
- RGEN Nasdaq
- CORT Nasdaq
- Market Cap
- RGEN 7.1B
- CORT 7.1B
- IPO Year
- RGEN N/A
- CORT N/A
- Fundamental
- Price
- RGEN $145.23
- CORT $71.79
- Analyst Decision
- RGEN Buy
- CORT Strong Buy
- Analyst Count
- RGEN 12
- CORT 4
- Target Price
- RGEN $175.56
- CORT $143.25
- AVG Volume (30 Days)
- RGEN 953.7K
- CORT 2.6M
- Earning Date
- RGEN 04-29-2025
- CORT 05-05-2025
- Dividend Yield
- RGEN N/A
- CORT N/A
- EPS Growth
- RGEN N/A
- CORT 30.85
- EPS
- RGEN N/A
- CORT 1.23
- Revenue
- RGEN $634,439,000.00
- CORT $675,040,000.00
- Revenue This Year
- RGEN $12.29
- CORT $36.81
- Revenue Next Year
- RGEN $15.20
- CORT $32.00
- P/E Ratio
- RGEN N/A
- CORT $58.37
- Revenue Growth
- RGEN 0.33
- CORT 39.94
- 52 Week Low
- RGEN $102.97
- CORT $22.00
- 52 Week High
- RGEN $182.52
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- RGEN 59.03
- CORT 53.90
- Support Level
- RGEN $125.05
- CORT $61.75
- Resistance Level
- RGEN $148.94
- CORT $71.15
- Average True Range (ATR)
- RGEN 10.09
- CORT 5.38
- MACD
- RGEN 3.52
- CORT -0.69
- Stochastic Oscillator
- RGEN 91.93
- CORT 61.78
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.